The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global COVID-19 RNA Vaccine Market Research Report 2025
Synopsis
RNA vaccines are leading the way in vaccines because they are particularly well suited to rapid development.Although no RNA vaccine has yet been approved, the threat of a pandemic is a great incentive to accelerate its progress.RNA vaccines consist of mrna strands.They are injected into the body, usually wrapped in lipid nanoparticles.They fuse with cells.Once inside the cell, the RNA sequence is translated by the ribosome into a protein or part of a protein.
The global COVID-19 RNA Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for COVID-19 RNA Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 RNA Vaccine.
Report Scope
The COVID-19 RNA Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global COVID-19 RNA Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the COVID-19 RNA Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
MODERNA
CureVac
Zydus Cadila
BioNTech
Stermirna
Segment by Type
Being Developed
Preclinical
Clinical I
Clinical II
Segment by Application
Pharmaceutical And Biotechnology Companies
Hospital
Academic And Research Organizations
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of COVID-19 RNA Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
RNA vaccines are leading the way in vaccines because they are particularly well suited to rapid development.Although no RNA vaccine has yet been approved, the threat of a pandemic is a great incentive to accelerate its progress.RNA vaccines consist of mrna strands.They are injected into the body, usually wrapped in lipid nanoparticles.They fuse with cells.Once inside the cell, the RNA sequence is translated by the ribosome into a protein or part of a protein.
The global COVID-19 RNA Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for COVID-19 RNA Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 RNA Vaccine.
Report Scope
The COVID-19 RNA Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global COVID-19 RNA Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the COVID-19 RNA Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
MODERNA
CureVac
Zydus Cadila
BioNTech
Stermirna
Segment by Type
Being Developed
Preclinical
Clinical I
Clinical II
Segment by Application
Pharmaceutical And Biotechnology Companies
Hospital
Academic And Research Organizations
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of COVID-19 RNA Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global COVID-19 RNA Vaccine Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Being Developed
1.2.3 Preclinical
1.2.4 Clinical I
1.2.5 Clinical II
1.3 Market by Application
1.3.1 Global COVID-19 RNA Vaccine Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical And Biotechnology Companies
1.3.3 Hospital
1.3.4 Academic And Research Organizations
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global COVID-19 RNA Vaccine Market Perspective (2019-2030)
2.2 COVID-19 RNA Vaccine Growth Trends by Region
2.2.1 Global COVID-19 RNA Vaccine Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 COVID-19 RNA Vaccine Historic Market Size by Region (2019-2024)
2.2.3 COVID-19 RNA Vaccine Forecasted Market Size by Region (2025-2030)
2.3 COVID-19 RNA Vaccine Market Dynamics
2.3.1 COVID-19 RNA Vaccine Industry Trends
2.3.2 COVID-19 RNA Vaccine Market Drivers
2.3.3 COVID-19 RNA Vaccine Market Challenges
2.3.4 COVID-19 RNA Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top COVID-19 RNA Vaccine Players by Revenue
3.1.1 Global Top COVID-19 RNA Vaccine Players by Revenue (2019-2024)
3.1.2 Global COVID-19 RNA Vaccine Revenue Market Share by Players (2019-2024)
3.2 Global COVID-19 RNA Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by COVID-19 RNA Vaccine Revenue
3.4 Global COVID-19 RNA Vaccine Market Concentration Ratio
3.4.1 Global COVID-19 RNA Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by COVID-19 RNA Vaccine Revenue in 2023
3.5 COVID-19 RNA Vaccine Key Players Head office and Area Served
3.6 Key Players COVID-19 RNA Vaccine Product Solution and Service
3.7 Date of Enter into COVID-19 RNA Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 COVID-19 RNA Vaccine Breakdown Data by Type
4.1 Global COVID-19 RNA Vaccine Historic Market Size by Type (2019-2024)
4.2 Global COVID-19 RNA Vaccine Forecasted Market Size by Type (2025-2030)
5 COVID-19 RNA Vaccine Breakdown Data by Application
5.1 Global COVID-19 RNA Vaccine Historic Market Size by Application (2019-2024)
5.2 Global COVID-19 RNA Vaccine Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America COVID-19 RNA Vaccine Market Size (2019-2030)
6.2 North America COVID-19 RNA Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America COVID-19 RNA Vaccine Market Size by Country (2019-2024)
6.4 North America COVID-19 RNA Vaccine Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe COVID-19 RNA Vaccine Market Size (2019-2030)
7.2 Europe COVID-19 RNA Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe COVID-19 RNA Vaccine Market Size by Country (2019-2024)
7.4 Europe COVID-19 RNA Vaccine Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific COVID-19 RNA Vaccine Market Size (2019-2030)
8.2 Asia-Pacific COVID-19 RNA Vaccine Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific COVID-19 RNA Vaccine Market Size by Region (2019-2024)
8.4 Asia-Pacific COVID-19 RNA Vaccine Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America COVID-19 RNA Vaccine Market Size (2019-2030)
9.2 Latin America COVID-19 RNA Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America COVID-19 RNA Vaccine Market Size by Country (2019-2024)
9.4 Latin America COVID-19 RNA Vaccine Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa COVID-19 RNA Vaccine Market Size (2019-2030)
10.2 Middle East & Africa COVID-19 RNA Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa COVID-19 RNA Vaccine Market Size by Country (2019-2024)
10.4 Middle East & Africa COVID-19 RNA Vaccine Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 MODERNA
11.1.1 MODERNA Company Detail
11.1.2 MODERNA Business Overview
11.1.3 MODERNA COVID-19 RNA Vaccine Introduction
11.1.4 MODERNA Revenue in COVID-19 RNA Vaccine Business (2019-2024)
11.1.5 MODERNA Recent Development
11.2 CureVac
11.2.1 CureVac Company Detail
11.2.2 CureVac Business Overview
11.2.3 CureVac COVID-19 RNA Vaccine Introduction
11.2.4 CureVac Revenue in COVID-19 RNA Vaccine Business (2019-2024)
11.2.5 CureVac Recent Development
11.3 Zydus Cadila
11.3.1 Zydus Cadila Company Detail
11.3.2 Zydus Cadila Business Overview
11.3.3 Zydus Cadila COVID-19 RNA Vaccine Introduction
11.3.4 Zydus Cadila Revenue in COVID-19 RNA Vaccine Business (2019-2024)
11.3.5 Zydus Cadila Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Detail
11.4.2 BioNTech Business Overview
11.4.3 BioNTech COVID-19 RNA Vaccine Introduction
11.4.4 BioNTech Revenue in COVID-19 RNA Vaccine Business (2019-2024)
11.4.5 BioNTech Recent Development
11.5 Stermirna
11.5.1 Stermirna Company Detail
11.5.2 Stermirna Business Overview
11.5.3 Stermirna COVID-19 RNA Vaccine Introduction
11.5.4 Stermirna Revenue in COVID-19 RNA Vaccine Business (2019-2024)
11.5.5 Stermirna Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global COVID-19 RNA Vaccine Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Being Developed
Table 3. Key Players of Preclinical
Table 4. Key Players of Clinical I
Table 5. Key Players of Clinical II
Table 6. Global COVID-19 RNA Vaccine Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global COVID-19 RNA Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global COVID-19 RNA Vaccine Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global COVID-19 RNA Vaccine Market Share by Region (2019-2024)
Table 10. Global COVID-19 RNA Vaccine Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global COVID-19 RNA Vaccine Market Share by Region (2025-2030)
Table 12. COVID-19 RNA Vaccine Market Trends
Table 13. COVID-19 RNA Vaccine Market Drivers
Table 14. COVID-19 RNA Vaccine Market Challenges
Table 15. COVID-19 RNA Vaccine Market Restraints
Table 16. Global COVID-19 RNA Vaccine Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global COVID-19 RNA Vaccine Market Share by Players (2019-2024)
Table 18. Global Top COVID-19 RNA Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 RNA Vaccine as of 2023)
Table 19. Ranking of Global Top COVID-19 RNA Vaccine Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by COVID-19 RNA Vaccine Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players COVID-19 RNA Vaccine Product Solution and Service
Table 23. Date of Enter into COVID-19 RNA Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global COVID-19 RNA Vaccine Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global COVID-19 RNA Vaccine Revenue Market Share by Type (2019-2024)
Table 27. Global COVID-19 RNA Vaccine Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global COVID-19 RNA Vaccine Revenue Market Share by Type (2025-2030)
Table 29. Global COVID-19 RNA Vaccine Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global COVID-19 RNA Vaccine Revenue Market Share by Application (2019-2024)
Table 31. Global COVID-19 RNA Vaccine Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global COVID-19 RNA Vaccine Revenue Market Share by Application (2025-2030)
Table 33. North America COVID-19 RNA Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America COVID-19 RNA Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America COVID-19 RNA Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe COVID-19 RNA Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe COVID-19 RNA Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe COVID-19 RNA Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific COVID-19 RNA Vaccine Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific COVID-19 RNA Vaccine Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific COVID-19 RNA Vaccine Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America COVID-19 RNA Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America COVID-19 RNA Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America COVID-19 RNA Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa COVID-19 RNA Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa COVID-19 RNA Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa COVID-19 RNA Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 48. MODERNA Company Detail
Table 49. MODERNA Business Overview
Table 50. MODERNA COVID-19 RNA Vaccine Product
Table 51. MODERNA Revenue in COVID-19 RNA Vaccine Business (2019-2024) & (US$ Million)
Table 52. MODERNA Recent Development
Table 53. CureVac Company Detail
Table 54. CureVac Business Overview
Table 55. CureVac COVID-19 RNA Vaccine Product
Table 56. CureVac Revenue in COVID-19 RNA Vaccine Business (2019-2024) & (US$ Million)
Table 57. CureVac Recent Development
Table 58. Zydus Cadila Company Detail
Table 59. Zydus Cadila Business Overview
Table 60. Zydus Cadila COVID-19 RNA Vaccine Product
Table 61. Zydus Cadila Revenue in COVID-19 RNA Vaccine Business (2019-2024) & (US$ Million)
Table 62. Zydus Cadila Recent Development
Table 63. BioNTech Company Detail
Table 64. BioNTech Business Overview
Table 65. BioNTech COVID-19 RNA Vaccine Product
Table 66. BioNTech Revenue in COVID-19 RNA Vaccine Business (2019-2024) & (US$ Million)
Table 67. BioNTech Recent Development
Table 68. Stermirna Company Detail
Table 69. Stermirna Business Overview
Table 70. Stermirna COVID-19 RNA Vaccine Product
Table 71. Stermirna Revenue in COVID-19 RNA Vaccine Business (2019-2024) & (US$ Million)
Table 72. Stermirna Recent Development
Table 73. Research Programs/Design for This Report
Table 74. Key Data Information from Secondary Sources
Table 75. Key Data Information from Primary Sources
List of Figures
Figure 1. Global COVID-19 RNA Vaccine Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global COVID-19 RNA Vaccine Market Share by Type: 2023 VS 2030
Figure 3. Being Developed Features
Figure 4. Preclinical Features
Figure 5. Clinical I Features
Figure 6. Clinical II Features
Figure 7. Global COVID-19 RNA Vaccine Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global COVID-19 RNA Vaccine Market Share by Application: 2023 VS 2030
Figure 9. Pharmaceutical And Biotechnology Companies Case Studies
Figure 10. Hospital Case Studies
Figure 11. Academic And Research Organizations Case Studies
Figure 12. Other Case Studies
Figure 13. COVID-19 RNA Vaccine Report Years Considered
Figure 14. Global COVID-19 RNA Vaccine Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global COVID-19 RNA Vaccine Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global COVID-19 RNA Vaccine Market Share by Region: 2023 VS 2030
Figure 17. Global COVID-19 RNA Vaccine Market Share by Players in 2023
Figure 18. Global Top COVID-19 RNA Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 RNA Vaccine as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by COVID-19 RNA Vaccine Revenue in 2023
Figure 20. North America COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America COVID-19 RNA Vaccine Market Share by Country (2019-2030)
Figure 22. United States COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe COVID-19 RNA Vaccine Market Share by Country (2019-2030)
Figure 26. Germany COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific COVID-19 RNA Vaccine Market Share by Region (2019-2030)
Figure 34. China COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America COVID-19 RNA Vaccine Market Share by Country (2019-2030)
Figure 42. Mexico COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa COVID-19 RNA Vaccine Market Share by Country (2019-2030)
Figure 46. Turkey COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia COVID-19 RNA Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. MODERNA Revenue Growth Rate in COVID-19 RNA Vaccine Business (2019-2024)
Figure 49. CureVac Revenue Growth Rate in COVID-19 RNA Vaccine Business (2019-2024)
Figure 50. Zydus Cadila Revenue Growth Rate in COVID-19 RNA Vaccine Business (2019-2024)
Figure 51. BioNTech Revenue Growth Rate in COVID-19 RNA Vaccine Business (2019-2024)
Figure 52. Stermirna Revenue Growth Rate in COVID-19 RNA Vaccine Business (2019-2024)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
